Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qing Re Huo Xue (QRHX) is a traditional Chinese medicine (TCM) formulation used primarily for the treatment of inflammatory and vascular conditions. It is most commonly administered as a decoction (Qingre Huoxue decoction; QRHXD), but also exists in external preparation forms (QRHXEP). The formula typically contains multiple herbal ingredients such as Ligusticum wallichii, Radix Paeoniae Rubra, Lignum acronychiae, Safflower (Carthamus tinctorius), Salvia miltiorrhiza (Danshen), Scutellaria baicalensis, and Ilex pubescens[7]. Its mechanism of action involves "clearing heat" and "promoting blood circulation," which translates to anti-inflammatory effects and improvement of microcirculation in biomedical terms. Modern studies suggest that it modulates angiogenic and inflammatory pathways[9], impacts metabolic pathways relevant to inflammation[2], delays radiological progression in rheumatoid arthritis[6], alleviates symptoms with fewer side effects than conventional DMARDs[1][3], promotes wound healing[4][9], and may have multi-targeted effects on cancer cells such as pancreatic cancer[5]. It is used both alone or adjunctively with standard therapies like methotrexate for rheumatoid arthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qing re huo xue.